Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03167619 |
|---|---|
| Brief Title: | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) |
| First Submitted : | May 23, 2017 |
| First Submitted that Met QC Criteria : | May 24, 2017 |
| First Posted : | May 30, 2017 |
| Results First Submitted : | June 30, 2022 |
| Results First Submitted that Met QC Criteria : | August 17, 2022 |
| Results First Posted : | September 13, 2022 |
| Last Update Submitted that Met QC Criteria : | August 17, 2022 |
| Last Update Posted : | September 13, 2022 |